SPR Therapeutics, LLC, a private medical device company that has developed a novel, evidence-based neurostimulation platform for chronic and acute pain, announced that it has appointed Michael P. Chuisano, former Vice President and Chief Operating Officer of Johnson & Johnson Innovation-JJDC, Inc.(JJDC), the venture subsidiary of Johnson & Johnson, to its board of directors effective immediately.

“Mike is a significant addition to the SPR board, and we are pleased to have his talents and experience as demonstrated across his successes at Johnson & Johnson as we develop and commercialize our novel, pain-management therapy through the SPRINT™ PNS System,” said Maria Bennett, Founder, President and CEO.  “I’m confident that his passion for identifying and advancing novel technologies to enhance patient lives, in a very complex healthcare system, will be of value to SPR.  His experience at JJDC, as well as his service as a director on numerous JJDC portfolio companies, will be of significant value to our board, and will help to shape the strategic direction of the company, while improving the quality of life for patients afflicted with debilitating acute and chronic pain.”

“It is an honor to join an organization, that under Maria’s leadership was founded on deep science and clinical validation, and is now positioned to be an emerging leader in the pain management field,” said Chuisano.  “I believe their novel, less-invasive peripheral nerve stimulation technology and approach incorporated into the SPRINT™ PNS System has the potential to significantly advance the treatment of chronic and acute pain without the use of opioids, and as it does not require permanent implantation, should further reduce invasiveness, risk and cost.”

Read the full release at GlobalNewswire.